Impact of diabetes on postinfarction heart failure and left ventricular remodeling

Helene von Bibra1, Martin St John Sutton

  • 1Klinic for Endocrinology, Diabetes and Vascular Medicine, Klinikum Bogenhausen, Städtische Klinikum München GmbH, Englschalkingerstrasse 77, 81925, München, Germany. vonbibra@gmx.de

Insights

Diabetes mellitus and insulin resistance worsen heart failure after heart attack. Metabolic changes impact heart muscle function and blood flow, leading to poor outcomes.

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Syndrome

Background:

  • Diabetes mellitus, metabolic syndrome, and insulin resistance are linked to diastolic dysfunction and reduced cardiac stress tolerance.
  • Heart failure in diabetic patients post-myocardial infarction has a poor prognosis.
  • Metabolic dysregulation from insulin resistance and hyperglycemia significantly affects cardiac myocyte function.

Purpose of the Study:

  • To review current data on diabetes and heart failure following acute myocardial infarction.
  • To explore the pathophysiologic mechanisms linking metabolic issues to cardiac dysfunction.
  • To discuss emerging diagnostic and therapeutic strategies for this patient population.

Main Methods:

  • Literature review of epidemiologic, pathophysiologic, diagnostic, and therapeutic data.
  • Synthesis of information on insulin resistance and hyperglycemia's impact on cardiac myocytes.
  • Analysis of current and future treatment approaches.

Main Results:

  • Diabetes and insulin resistance are significant contributors to heart failure post-myocardial infarction.
  • Metabolic factors critically regulate microvascular perfusion and myocyte energy production.
  • Current therapeutic strategies require further investigation for optimal outcomes.

Conclusions:

  • Understanding the metabolic impact of diabetes is crucial for managing heart failure post-myocardial infarction.
  • Novel therapeutic strategies targeting metabolic pathways show promise.
  • Further research is needed to improve prognosis for diabetic patients with heart failure.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...